EISAI AND KEIO UNIVERSITY TO ESTABLISH A NEW INDUSTRY-ACADEMIA COLLABORATION SITE: ACCELERATING THE DISCOVERY OF NOVEL DRUG TARGETS THAT MAY LEAD TO DEVELOPMENT OF NEW THERAPEUTICS FOR DEMENTIA
December 22, 2016
Eisai Co., Ltd. Keio University
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Keio University (President: Atsushi Seike) announced today that they have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.
Under this joint research agreement, Eisai and Keio University will establish the Eisai-Keio Innovation Lab for Dementia (tentative name) as a base for industry-academia collaboration within Keio University’s Shinanomachi campus (Shinjuku ward, Tokyo) that will hopefully spur new innovation in the treatment of dementia. The lab will be an integrated research site for clinical medicine and basic medicine, and will be staffed by experienced researchers from both organizations.